Ryzodeg®

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2

Unknown Phase

A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

CompletedNCT04656106

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2021-04-27End: 2021-07-01Updated: 2021-09-28

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

CompletedNCT05221580

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-03-18End: 2023-03-31Updated: 2024-06-14

Related Papers

19-PUB: Improved Glycemic Control in People with Type 2 Diabetes (T2D) Initiating or Switching to Insulin Degludec/Insulin Aspart (IDegAsp) in a Real-World Setting in China

Diabetes2024-06-14

Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus

Diabetes & Metabolism Journal2024-02-273 citations